Cancer is a continuation of the evolutionary process on a cellular scale. The mutations that define this evolutionary process show a marked variety of complexity, which I have explored in this work. First, I have explored the genomics of osteoblastoma, a rare benign bone tumour. This work, for the first time, demonstrates that osteoblastoma and the related entity, osteoid osteoma, are defined by structural rearrangements in the AP-1 family of genes, FOS and FOSB. This original work is the first report of a FOS mutation in a human bone-forming tumour since its discovery as one of the archetypal proto-oncogenes, forming the basis of a much-needed diagnostic test. Giant cell tumours (GCTs) of bone are characterised by an H3.3 gene mutation. I ...
Undifferentiated pleomorphic sarcoma now falls under the broader rubric of undifferentiated soft tis...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...
Cancer is a continuation of the evolutionary process on a cellular scale. The mutations that define ...
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3...
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3...
Primary tumours of bone are heterogenous and infrequent neoplasms. Distinguishing between benign, in...
Accelerating technological advances have allowed the widespread genomic profiling of tumors. As yet,...
BACKGROUND: Giant Cell Tumour of Bone (GCT) is a locally aggressive primary bone tumour that usuall...
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the ...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Two studies by Nik-Zainal et al. and a study by Roberts et al. now provide new insights into the lif...
BACKGROUND: Whole-genome sequencing studies have recently shown that osteosarcomas (OSs) display ...
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by w...
Bone tumours are difficult to diagnose and treat, as they are rare and over 60 different subtypes ar...
Undifferentiated pleomorphic sarcoma now falls under the broader rubric of undifferentiated soft tis...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...
Cancer is a continuation of the evolutionary process on a cellular scale. The mutations that define ...
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3...
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3...
Primary tumours of bone are heterogenous and infrequent neoplasms. Distinguishing between benign, in...
Accelerating technological advances have allowed the widespread genomic profiling of tumors. As yet,...
BACKGROUND: Giant Cell Tumour of Bone (GCT) is a locally aggressive primary bone tumour that usuall...
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the ...
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has his...
Two studies by Nik-Zainal et al. and a study by Roberts et al. now provide new insights into the lif...
BACKGROUND: Whole-genome sequencing studies have recently shown that osteosarcomas (OSs) display ...
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by w...
Bone tumours are difficult to diagnose and treat, as they are rare and over 60 different subtypes ar...
Undifferentiated pleomorphic sarcoma now falls under the broader rubric of undifferentiated soft tis...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following...